Grufity logo
Grufity logo
BRTX

BRTX - BioRestorative Therapies, Inc. Stock Price, Fair Value and News

$2.70+0.03 (+1.12%)
Delayed as of 14 Sep 2026, 04:00 pm ET

BRTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BRTX Price Action

Last 7 days

1713.3%

Last 30 days

1082.6%

Last 90 days

677.1%

Trailing 12 Months

76.6%

BRTX RSI Chart

BRTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BRTX Valuation

Market Cap

68.8M

Price/Earnings (Trailing)

-6.22

Price/Sales (Trailing)

192.22

EV/EBITDA

-0.4

Price/Free Cashflow

-5.82

BRTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

BRTX Fundamentals

BRTX Revenue

Revenue (TTM)

357.9K

Rev. Growth (Yr)

-86.63%

Rev. Growth (Qtr)

18.21%

BRTX Earnings

Earnings (TTM)

-11.1M

Earnings Growth (Yr)

59.65%

Earnings Growth (Qtr)

32.84%

BRTX Profitability

EBT Margin

-3968.06%

Return on Equity

-365.43%

Return on Assets

-238.27%

Free Cashflow Yield

-17.2%

BRTX Investor Care

Shares Dilution (1Y)

204.87%

Diluted EPS (TTM)

-1.06

Revenue & Growth

How BioRestorative Therapies, Inc. generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026357.9K---
2025390.7K380.4K370.0K359.7K
2024149.5K174.1K377.0K401.0K
2023135.1K128.5K130.2K145.8K
202244.0K100.1K121.1K119.8K
202169.0K65.0K58.0K46.0K
2020127.0K115.0K92.0K77.0K
2019121.0K115.0K127.0K130.0K
201893.0K110.0K120.0K111.0K
201734.2K38.1K49.1K81.0K
2016480.8K332.6K184.5K36.4K
2015600.5K573.3K509.5K628.9K
2014-301.6K358.8K416.0K
201372.8K130.0K187.2K244.4K
2012---15.6K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About BioRestorative Therapies, Inc.

BRTX
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.
 CEO
 WEBSITEbiorestorative.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES10

BioRestorative Therapies, Inc. Frequently Asked Questions

BRTX is the stock ticker symbol of BioRestorative Therapies, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Sep 14 2026, market cap of BioRestorative Therapies, Inc. is 68.79 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Sep 14 2026, BRTX's PE ratio (Price to Earnings) is -6.22 and Price to Sales (PS) ratio is 192.22. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BRTX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, BioRestorative Therapies, Inc. has provided -0.573 (multiply by 100 for percentage) rate of return.